| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470150A2 Corticosteroids nitrate derivatives |
| 10/27/2004 | EP1470145A2 Methods and materials for modulating p2x2 |
| 10/27/2004 | EP1470138A1 Mmp inhibitors |
| 10/27/2004 | EP1470137A1 Edg receptor agonists |
| 10/27/2004 | EP1470130A2 Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno 2,3-b 1,5 benzodiazepine |
| 10/27/2004 | EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| 10/27/2004 | EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |
| 10/27/2004 | EP1470122A1 Rho-kinase inhibitors |
| 10/27/2004 | EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 10/27/2004 | EP1470112A1 Substituted pyridazinones as inhibitors of p38 |
| 10/27/2004 | EP1470101A1 New opioid derivative |
| 10/27/2004 | EP1469882A2 Treatment of ms with goat serum |
| 10/27/2004 | EP1469875A1 Compositions and methods for modulating connexin hemichannels |
| 10/27/2004 | EP1469862A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions |
| 10/27/2004 | EP1469856A2 8-heteroaryl xanthine adenosine a sb 2b /sb receptor antagonists |
| 10/27/2004 | EP1469855A2 Methods of treating patients suffering from movement disorders |
| 10/27/2004 | EP1469854A1 Condensed heterocyclic compounds |
| 10/27/2004 | EP1469852A2 Nitric oxide donors for treatment of disease and injury |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469848A1 Sedative non-benzodiazepine formulations |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1469842A2 Bicyclic cb2 cannabinoid receptor ligands |
| 10/27/2004 | EP1469835A2 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 10/27/2004 | EP1469812A2 Oral insulin therapy |
| 10/27/2004 | EP1469810A2 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders |
| 10/27/2004 | EP1469769A2 Novel compositions and methods for cancer |
| 10/27/2004 | EP1469734A1 Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| 10/27/2004 | EP1469730A2 Methods and compositions for treating parkinson's disease |
| 10/27/2004 | EP1469717A2 Triple transgenic mouse model of alzheimer's disease |
| 10/27/2004 | EP1373263B1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 10/27/2004 | EP1299126B1 Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases |
| 10/27/2004 | EP1246791B1 Aminomethyl-phenyl-cyclohexanone derivatives |
| 10/27/2004 | EP1212061B1 Injectable buprenorphine microparticle compositions and their use in reducing consumption of heroin and alcohol |
| 10/27/2004 | EP1204407B1 Implantable active ingredient depot |
| 10/27/2004 | EP1079860B1 Nicotine immunogen |
| 10/27/2004 | EP0813544B1 Bradykinin antagonist peptides incorporating n-substituted glycines |
| 10/27/2004 | EP0763107B1 Pantropic neurotrophic factors |
| 10/27/2004 | CN1541335A EPF receptor assays, compounds and therapeutic compsns. |
| 10/27/2004 | CN1541278A Novel molecular target for neurotoxicity |
| 10/27/2004 | CN1541262A Hops extracts, method for prodn. and use |
| 10/27/2004 | CN1541225A Humanized antibodies that recognize beta amyloid peptide |
| 10/27/2004 | CN1541217A Chemical compounds |
| 10/27/2004 | CN1541216A 8-methoxy-(1,2,4) triazolo (1,5-A) pyridine derivatives and their use as adenosine receptor ligands |
| 10/27/2004 | CN1541214A Novel compounds |
| 10/27/2004 | CN1541211A Derivatives of N-(arylsulfonyl) beta-aminoacids comprising substituted aminomethyl group, prepn. method thereof and pharmaceutical compsns. contg same |
| 10/27/2004 | CN1541210A Arylsulfonyl derivatives with 5-HT6 receptor affinity |
| 10/27/2004 | CN1541203A 4-(phenyl-(piperidin-4-YL)-amino)-benzamide derivatives and their use for treatment of pain, anxiety or gastrointestinal disorders |
| 10/27/2004 | CN1541112A Percutaneous absorption preparations |
| 10/27/2004 | CN1541107A Growth factor complex |
| 10/27/2004 | CN1541106A Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 10/27/2004 | CN1541105A Combination therapies using vitamin B12 and interferon for treatment of viral, provliferative and inflammatory diseases |
| 10/27/2004 | CN1541102A Somatostain agonists |
| 10/27/2004 | CN1541099A Arylazo-substituted imidazole for treatment of stress urinary incontinence |
| 10/27/2004 | CN1541093A Novel use of combined 5-HI1A agonists and selective serotonin reuptake inhibitors |
| 10/27/2004 | CN1541092A Method for treating primary insomnia |
| 10/27/2004 | CN1539843A **Tc marked dopamine transport protein developer |
| 10/27/2004 | CN1539824A Compounds with analygesic effect |
| 10/27/2004 | CN1539497A Combinaton of medication for treating depression and preparation method |
| 10/27/2004 | CN1539461A Preparation of stabilizing brain for curing apoplexy and migraine and producing method |
| 10/27/2004 | CN1539449A Magnetism and drug combined type fragrnant baldric for avoiding plague |
| 10/27/2004 | CN1539419A Compound preparation of reveratrol and application |
| 10/27/2004 | CN1539409A Method for preparing injection of contenton |
| 10/27/2004 | CN1172953C Gene sequence and amino-acid sequence of varient omega-conch toxin polypeptide and their preparing method and medicinal use |
| 10/27/2004 | CN1172929C Substituted indoles for modulating NFKB activity |
| 10/27/2004 | CN1172919C Alkyl alcohol piperazine derivativ and its application in preparing medicine for treating depression |
| 10/27/2004 | CN1172695C Medicine for preventing and treating senile dementia |
| 10/27/2004 | CN1172669C Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 10/27/2004 | CN1172663C Application of gamma-vinyl-gamma-azyl butyrate in treatment of addition and addiction-related behavior |
| 10/26/2004 | US6809199 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| 10/26/2004 | US6809175 Cadherin derived growth factor and its use |
| 10/26/2004 | US6809119 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases |
| 10/26/2004 | US6809116 Materials and methods for the treatment of depression |
| 10/26/2004 | US6809111 Antiinflammatory agents; analgesics |
| 10/26/2004 | US6809107 Neurodegenerative diseases |
| 10/26/2004 | US6809105 Diazabicyclic central nervous system active agents |
| 10/26/2004 | US6809104 Comprises 6h-pyrido(4,3-b)carbazole-containing compounds for treatment of obesity, eating/anxiety/mood disorders and other diseases mediated by g-protein-coupled-receptors and melanin-concentrating hormone receptors |
| 10/26/2004 | US6809100 Hydroxamic acid derivatives |
| 10/26/2004 | US6809094 N-fused hetercyclo-1,4- or -1,5- diazabicyclo derivatives; nicotinic receptor agonists; central nervous system (cns) |
| 10/26/2004 | US6809092 1,3,4,5-tetrahydro-2h-2-benzazepin-2-yl derivatives; cysteine protease inhibitors |
| 10/26/2004 | US6809090 Nitrogen monoxide synthase and/or lipidic peroxidation inhibitors |
| 10/26/2004 | US6809089 Sulfonylaminocarboxylic acid N-arylamides as guanylate cyclase activators |
| 10/26/2004 | US6809077 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration |
| 10/26/2004 | US6808912 For diagnosis/therapy of inflammation, cancer, arteriosclerosis, and psoriasis |
| 10/26/2004 | US6808739 Drying method for selectively removing volatile components from wet coatings |
| 10/26/2004 | US6808712 Imunogenic a beta fragment linked to immunoglobulin carrier to form conjugate; adjuvant comprising antibodies to a beta fragment enhances immune response; alzheimer*s disease treatment |
| 10/26/2004 | US6808710 Contacting cell expressing pd-1 with binding agent; genetic transduction of negative signal |
| 10/26/2004 | CA2295752C Novel process for manufacturing paroxetine solid dispersions |
| 10/26/2004 | CA2266759C 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase |
| 10/21/2004 | WO2004090541A1 METHOD OF SCREENING DRUG WITH THE USE OF 67 kDa LAMININ RECEPTOR AND DRUG OBTAINED THEREBY |
| 10/21/2004 | WO2004089965A2 Topiramate and processes for the preparation thereof |
| 10/21/2004 | WO2004089956A1 Novel amino acid dysiherbaine |
| 10/21/2004 | WO2004089951A1 Imidazopyridine derivatives having an affinity for melanocortin receptors |
| 10/21/2004 | WO2004089949A1 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands |
| 10/21/2004 | WO2004089942A2 Benzimidazolidinone derivatives as muscarinic agents |
| 10/21/2004 | WO2004089939A1 Condensed furan derivatives as adenosine antagonists |
| 10/21/2004 | WO2004089936A1 Heteroarylsulfonanilide derivative and medicinal composition containing the same |
| 10/21/2004 | WO2004089931A1 Substituted pyrazoles |
| 10/21/2004 | WO2004089925A1 Pi-3 kinase inhibitor prodrugs |
| 10/21/2004 | WO2004089913A1 Aminopyrimidine derivatives and their medical use |